Risheng Ma1, Syed Morshed, Rauf Latif, Mone Zaidi, Terry F Davies. 1. Thyroid Research Unit, Mount Sinai School of Medicine and James J Peters Veterans Affairs Medical Center, New York, New York 10468, USA. risheng.ma@mssm.edu
Abstract
BACKGROUND: We have shown that thyroid-stimulating hormone (TSH) has a direct inhibitory effect on osteoclastic bone resorption and that TSH receptor (TSHR) null mice display osteoporosis. To determine the stage of osteoclast development at which TSH may exert its effect, we examined the influence of TSH and agonist TSHR antibodies (TSHR-Ab) on osteoclast differentiation from murine embryonic stem (ES) cells to gain insight into bone remodeling in hyperthyroid Graves' disease. METHODS: Osteoclast differentiation was initiated in murine ES cell cultures through exposure to macrophage colony stimulation factor, receptor activator of nuclear factor кB ligand, vitamin D, and dexamethasone. RESULTS: Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts formed in ~12 days. This coincided with the expected downregulation of known markers of self renewal and pluripotency (including Oct4, Sox2, and REX1). Both TSH and TSHR-Abs inhibited osteoclastogenesis as evidenced by decreased development of TRAP-positive cells (~40%-50% reduction, p = 0.0047), and by decreased expression, in a concentration-dependent manner, of osteoclast differentiation markers (including the calcitonin receptor, TRAP, cathepsin K, matrix metallo-proteinase-9, and carbonic anhydrase II). Similar data were obtained using serum immunoglobulin-Gs (IgGs) from patients with hyperthyroid Graves' disease and known TSHR-Abs. TSHR stimulators inhibited tumor necrosis factor-alpha mRNA and protein expression, but increased the expression of osteoprotegerin (OPG), an antiosteoclastogenic human soluble receptor activator of nuclear factor кB ligand receptor. Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG. CONCLUSION: These data establish ES-derived osteoclastogenesis as an effective model system to study the regulation of osteoclast differentiation in early development. The results support the observations that TSH has a bone protective action by negatively regulating osteoclastogenesis. Further, our results implicate TSHR-Abs in offering skeletal protection in hyperthyroid Graves' disease, even in the face of high thyroid hormone and low TSH levels.
BACKGROUND: We have shown that thyroid-stimulating hormone (TSH) has a direct inhibitory effect on osteoclastic bone resorption and that TSH receptor (TSHR) null mice display osteoporosis. To determine the stage of osteoclast development at which TSH may exert its effect, we examined the influence of TSH and agonist TSHR antibodies (TSHR-Ab) on osteoclast differentiation from murine embryonic stem (ES) cells to gain insight into bone remodeling in hyperthyroid Graves' disease. METHODS: Osteoclast differentiation was initiated in murine ES cell cultures through exposure to macrophage colony stimulation factor, receptor activator of nuclear factor кB ligand, vitamin D, and dexamethasone. RESULTS:Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts formed in ~12 days. This coincided with the expected downregulation of known markers of self renewal and pluripotency (including Oct4, Sox2, and REX1). Both TSH and TSHR-Abs inhibited osteoclastogenesis as evidenced by decreased development of TRAP-positive cells (~40%-50% reduction, p = 0.0047), and by decreased expression, in a concentration-dependent manner, of osteoclast differentiation markers (including the calcitonin receptor, TRAP, cathepsin K, matrix metallo-proteinase-9, and carbonic anhydrase II). Similar data were obtained using serum immunoglobulin-Gs (IgGs) from patients with hyperthyroid Graves' disease and known TSHR-Abs. TSHR stimulators inhibited tumor necrosis factor-alpha mRNA and protein expression, but increased the expression of osteoprotegerin (OPG), an antiosteoclastogenic human soluble receptor activator of nuclear factor кB ligand receptor. Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG. CONCLUSION: These data establish ES-derived osteoclastogenesis as an effective model system to study the regulation of osteoclast differentiation in early development. The results support the observations that TSH has a bone protective action by negatively regulating osteoclastogenesis. Further, our results implicate TSHR-Abs in offering skeletal protection in hyperthyroid Graves' disease, even in the face of high thyroid hormone and low TSH levels.
Authors: T Kuber Sampath; Petra Simic; Rebecca Sendak; Natasa Draca; Ann E Bowe; Stephen O'Brien; Susan C Schiavi; John M McPherson; Slobodan Vukicevic Journal: J Bone Miner Res Date: 2007-06 Impact factor: 6.741
Authors: J Sanders; J Jeffreys; H Depraetere; M Evans; T Richards; A Kiddie; K Brereton; L D K E Premawardhana; D Y Chirgadze; R Núñez Miguel; T L Blundell; J Furmaniak; B Rees Smith Journal: Thyroid Date: 2004-08 Impact factor: 6.568
Authors: K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda Journal: J Exp Med Date: 2000-01-17 Impact factor: 14.307
Authors: J H Duncan Bassett; Allan J Williams; Elaine Murphy; Alan Boyde; Peter G T Howell; Rowan Swinhoe; Marta Archanco; Frédéric Flamant; Jacques Samarut; Sabine Costagliola; Gilbert Vassart; Roy E Weiss; Samuel Refetoff; Graham R Williams Journal: Mol Endocrinol Date: 2007-10-11
Authors: Ramkumarie Baliram; Rauf Latif; Joshua Berkowitz; Simon Frid; Graziana Colaianni; Li Sun; Mone Zaidi; Terry F Davies Journal: Proc Natl Acad Sci U S A Date: 2011-09-12 Impact factor: 11.205
Authors: Ramkumarie Baliram; Li Sun; Jay Cao; Jianhua Li; Rauf Latif; Amanda K Huber; Tony Yuen; Harry C Blair; Mone Zaidi; Terry F Davies Journal: J Clin Invest Date: 2012-09-17 Impact factor: 14.808
Authors: G Ramajayam; R C Vignesh; S Karthikeyan; K Senthil Kumar; G D Karthikeyan; S Veni; M Sridhar; J Arunakaran; M Michael Aruldhas; N Srinivasan Journal: Mol Cell Biochem Date: 2012-06-07 Impact factor: 3.396
Authors: Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen Journal: J Endocrinol Date: 2018-03-19 Impact factor: 4.286
Authors: Li Sun; Ling-Ling Zhu; Ping Lu; Tony Yuen; Jianhua Li; Risheng Ma; Ramkumarie Baliram; Ramkumari Baliram; Surinder S Moonga; Peng Liu; Alberta Zallone; Maria I New; Terry F Davies; Mone Zaidi Journal: Proc Natl Acad Sci U S A Date: 2013-05-28 Impact factor: 11.205
Authors: M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti Journal: J Endocrinol Invest Date: 2020-07-21 Impact factor: 4.256
Authors: R Baliram; A Chow; A K Huber; L Collier; M R Ali; S A Morshed; R Latif; A Teixeira; M Merad; L Liu; L Sun; H C Blair; M Zaidi; T F Davies Journal: Endocrinology Date: 2013-10-18 Impact factor: 4.736
Authors: Elżbieta Skowrońska-Jóźwiak; Kinga Krawczyk-Rusiecka; Krzysztof C Lewandowski; Zbigniew Adamczewski; Andrzej Lewiński Journal: Thyroid Res Date: 2012-11-13